Philip V. Theodosopoulos

Philip V. Theodosopoulos

Auto-generated profile, based on publicly available information

Philip V. Theodosopoulos

Department of Neurosurgery, University of California, San Francisco, San Francisco, California, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
HOHirokazu Ogino
Hirokazu Ogino
JTJennie W. Taylor
Jennie W. Taylor
TNTakahide Nejo
Takahide Nejo
DGDavid Gibson
David Gibson
PWPayal B. Watchmaker
Payal B. Watchmaker
HOHideho Okada
Hideho Okada
BACKGROUND. Long-term prognosis of WHO grade II low-grade gliomas (LGGs) is poor, with a high risk of recurrence and malignant transformation into high-grade gliomas. Given the relatively intact immune system of patients with LGGs and the slow tumor growth rate, vaccines are an attractive treatment strategy. METHODS. We conducted a pilot study to evaluate the safety and immunological effects of vaccination with GBM6-AD, lysate of an allogeneic glioblastoma stem cell line, with poly-ICLC in patients with LGGs. Patients were randomized to receive the vaccines before surgery (arm 1) or not (arm 2) and all patients received adjuvant vaccines. Coprimary outcomes were to evaluate safety and immune response in the tumor. RESULTS. A total of 17 eligible patients were enrolled — 9 in arm 1 and 8 in arm 2. This regimen was well tolerated with no regimen-limiting toxicity. Neoadjuvant vaccination induced upregulation of type-1 cytokines and chemokines and increased activated CD8+ T cells in peripheral blood. Single-cell RNA/T cell receptor sequencing detected CD8+ T cell clones that expanded with effector phenotype and migrated into the tumor microenvironment (TME) in response to neoadjuvant vaccination. Mass cytometric analyses detected increased tissue resident–like CD8+ T cells with effector memory phenotype in the TME after the neoadjuvant vaccination. CONCLUSION. The regimen induced effector CD8+ T cell response in peripheral blood and enabled vaccine-reactive CD8+ T cells to migrate into the TME. Further refinements of the regimen may have to be integrated into future strategies. TRIAL REGISTRATION. ClinicalTrials.gov NCT02549833. FUNDING. NIH (1R35NS105068, 1R21CA233856), Dabbiere Foundation, Parker Institute for Cancer Immunotherapy, and Daiichi Sankyo Foundation of Life Science.

3 January 2014 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
SGSanjeet S. Grewal
Sanjeet S. Grewal
AKAlmaz Kurbanov
Almaz Kurbanov
AAAmjad Anaizi
Amjad Anaizi
JKJeffrey T. Keller
Jeffrey T. Keller
PTPhilip V. Theodosopoulos
Philip V. Theodosopoulos
LZLee A. Zimmer
Lee A. Zimmer

24 May 2017 in Operative Neurosurgery
Verified
Journal Article
Open access
PDF file
MSMichael M Safaee
Michael M Safaee
MMMichael W McDermott
Michael W McDermott
ABArnau Benet
Arnau Benet
PTPhilip V Theodosopoulos
Philip V Theodosopoulos
BACKGROUND: Open transcranial approaches to the anterior skull base remain an integral component of current skull base practice. Evolution of these and other techniques has resulted in revisions of standard, tried-and-true methods in attempts to improve patient outcomes and cosmesis, while still providing the best combination of surgical exposure and ergonomics. OBJECTIVE: To describe a modified approach for midline tumors of the anterior skull base. METHODS: We describe the anatomy and techniques of a modified extended bifrontal craniotomy for anterior skull base tumors. Case examples and a postoperative 3-dimensional computed tomographic reconstruction of the craniotomy are provided. RESULTS: The technique has been employed with success in 3 tuberculum sellae meningiomas where the anterior limit of the tumor is several centimeters back from the inner table of the frontal bone. The mean distance from the tumor to inner table was 2.8 cm (range 1.3-3.8 cm). Mean tumor dimensions were 3.0 cm (transverse), 3.5 cm (anterior-posterior), and 2.2 cm (craniocaudal). Average operative time was 557 min. No cases had new T2/fluid-attenuated inversion recovery magnetic resonance imaging signal of the inferior frontal lobe to indicate retraction injury. CONCLUSION: The tailored extended bifrontal craniotomy for anterior skull base tumors provides adequate access to the anterior cranial fossa and has replaced our standard extended bifrontal approach. Keeping the osteotomy cut lines outside of the orbit reduces orbital swelling and mechanical disruption of conjugate eye movements in the early postoperative period, while allowing for minimal frontal lobe retraction and providing sufficient surgical exposure along the anterior skull base.

31 May 2020 in Cureus
Verified
Journal Article
Open access
PDF file
YLYoung M. Lee
Young M. Lee
AOAngel Ordaz
Angel Ordaz
BDBeata Durcanova
Beata Durcanova
JVJennifer A Viner
Jennifer A Viner
PTPhilip V. Theodosopoulos
Philip V. Theodosopoulos
MMMichael W. McDermott
Michael W. McDermott
Posterior fossa craniotomies can be complicated by cerebrospinal fluid (CSF) leaks, infection, meningitis, neurologic deficits, and intracranial hypotension caused by defective closure of the dura. Secondary dural closures such as pericranial graft, muscle graft, glue, sealants, or fat graft are used. However, there have been few studies examining the use of sealants with a polyethylene glycol and polyethylenimine component. We studied the effect of one such sealant, Adherus® (HyperBranch Medical Technology, Durham, NC, USA), as an adjunct to secondary closure methods in the reduction of the use of abdominal fat grafting and lumbar puncture/drains. We retrospectively reviewed the surgical records of all patients undergoing posterior fossa cranial surgery during a two-year period at a tertiary university affiliated medical center. Overall, data a total of 122 patients (62 in the no Adherus and 60 in the Adherus group) were collected. There was no statistically significant difference in the 30-day incisional CSF leak rate (4.1% vs. 6.5%; p=0.183), 30-day non-incisional CSF leak rate (11.3% vs. 5.0%; p=0.205), and 30-day pseudomeningocele rate (16.1% vs. 13.3%; p=0.663) in the no Adherus and Adherus groups, respectively. However, there was a significant reduction in the use of abdominal fat grafting (0% vs. 30.7%; p<0.001) and intraoperative CSF diversion techniques (58.1% vs. 23.3%; p<0.001). Every instance of the use of Adherus saved on average, $809.36. A statistically significant reduction in the use of CSF shunting procedures during posterior fossa craniotomy/craniectomy was achieved after the introduction of Adherus with no increase in CSF leak rate.

1 September 2021 in Journal of Clinical Neuroscience
Verified
Journal Article
Closed access
PDF file
NJNicole T. Jiam
Nicole T. Jiam
ADAbel P. David
Abel P. David
EFEric J. Formeister
Eric J. Formeister
JGJose Gurrola
Jose Gurrola
MAManish K. Aghi
Manish K. Aghi
IEIvan H. El-Sayed
Ivan H. El-Sayed

10 September 2021 in Journal of Neurological Surgery Part B: Skull Base
Verified
Journal Article
Closed access
PDF file
AAAlexander A. Aabedi
Alexander A. Aabedi
JYJacob S. Young
Jacob S. Young
RPRyan R. L. Phelps
Ryan R. L. Phelps
EWEthan A. Winkler
Ethan A. Winkler
MMMichael W. McDermott
Michael W. McDermott
PTPhilip V. Theodosopoulos
Philip V. Theodosopoulos
Introduction The management of recurrent craniopharyngioma is complex with limited data to guide decision-making. Some reports suggest reoperation should be avoided due to an increased complication profile, while others have demonstrated that safe reoperation can be performed. For other types of skull base lesions, maximal safe resection followed by adjuvant therapy has replaced radical gross total resection due to the favorable morbidity profiles. Methods Seventy-one patients underwent resection over a 9-year period for craniopharyngioma and were retrospectively reviewed. Patients were separated into primary resection and reoperation cohorts and stratified by surgical approach (endonasal vs. cranial) and survival analyses were performed based on cohort and surgical approach. Results Fifty patients underwent primary resection, while 21 underwent reoperation for recurrence. Fifty endonasal transsphenoidal surgeries and 21 craniotomies were performed. Surgical approaches were similarly distributed across cohorts. Subtotal resection was achieved in 83% of all cases. There were no differences in extent of resection, visual outcomes, subsequent neuroendocrine function, and complications across cohorts and surgical approaches. The median time to recurrence was 87 months overall, and there were no differences by cohort and approach. The 5-year survival rate was 81.1% after reoperation versus 93.2% after primary resection. Conclusion Compared with primary resection, reoperation for craniopharyngioma recurrence is associated with similar functional and survival outcomes in light of individualized surgical approaches. Maximal safe resection followed by adjuvant radiotherapy for residual tumor likely preserves vision and endocrine function without sacrificing overall patient survival.